Vantage logo

Bristol scores early

The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.

Vantage logo

Bristol bets big on Myokardia

The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.